CLAIMS
1. An antifungal composition comprising at least one antifungal agent, at least one fatty acid or ester thereof, and optionally one or more excipient, wherein the antifungal agent is selected from the group consisting of allylamines, benzylamines, azoles, polyenes, echinocandins, N-hydroxy pyridone, N-hydroxy pyrithione or metal coordination complexes, tavaborole, flucytosine, griseofulvin, hinokitol and combinations thereof; wherein the fatty acid has a carbon chain length ranging from C-l to C-14; and wherein the composition has synergistic antifungal activity.
2. The antifungal composition of claim 1, wherein the fatty acid or ester thereof is a saturated or unsaturated fatty acid or ester of said saturated or unsaturated fatty acid.
3. The antifungal composition of any of the preceding claims, wherein the fatty acid has a carbon chain length ranging from C-l 1 to C-14.
4. The antifungal composition of any of the preceding claims, wherein the fatty acid has a carbon chain length ranging from C-l to C-l0.
5. The antifungal composition of any of the preceding claims, wherein the fatty acid is selected from the group consisting of formic acid (CI), acetic acid (C2), propionic acid (C3), butyric acid (C4), valeric acid (C5), caproic acid (C6), enanthic acid (C7), caprylic acid (C8), pelargonic acid (C9), capric acid (CIO), undecylenic acid (CI 1), lauric acid (C12), tridecylic acid (C13), myristic acid (C14) and corresponding unsaturated fatty acids thereof.
6. The antifungal composition of any of the preceding claims, wherein the fatty acid is undecylenic acid (CI 1), lauric acid (C12), tridecylic acid (C13), myristic acid (C14) or corresponding unsaturated fatty acids thereof.
7. The antifungal composition of any of the preceding claims, wherein the fatty acid is formic acid (CI), acetic acid (C2), propionic acid (C3), butyric acid (C4), valeric acid (C5), caproic acid (C6), enanthic acid (C7), caprylic acid (C8), pelargonic acid (C9), capric acid (CIO) or corresponding unsaturated fatty acids thereof.
8. The antifungal composition of any of the preceding claims, wherein the fatty acid ester is selected from the group consisting of ester of formic acid (CI), ester of acetic acid (C2), ester of propionic acid (C3), ester of butyric acid (C4), ester of valeric acid (C5), ester of caproic acid (C6), ester of enanthic acid (C7), ester of caprylic acid (C8), ester of pelargonic acid (C9), ester of capric acid (CIO), ester of undecylenic acid (CI 1),

ester of lauric acid (C12), ester of tridecylic acid (C13), ester of myristic acid (C14) and esters of corresponding unsaturated fatty acids thereof.
9. The antifungal composition of any of the preceding claims, wherein the fatty acid ester is selected from the group consisting of propylene glycol monocaprylate, propylene glycol monolaurate, propylene glycol monocaprate, glyceryl monocaprylate, glyceryl monolaurate, glyceryl monocaprate, glyceryl dicaprylate, glyceryl dilaurate, glyceryl dicaprate, glyceryl mono and di caprate, glyceryl mono and di caprylate, glyceryl mono and di laurate, triglycerides of caprylic acid, capric acid, lauric acid and their mixtures, and combinations thereof.
10. The antifungal composition of any of the preceding claims, wherein the fatty acid ester is propylene glycol monocaprylate, propylene glycol monolaurate, glycerol monocaprylate, glycerol monolaurate, or any combination thereof.
11. The antifungal composition of any of the preceding claims, wherein the N-hydroxy pyridone is piroctone olamine, ciclopirox olamine or a combination thereof; the N-hydroxy pyrithione or the metal coordination complex is zinc pyrithione or any respective bivalent metal co-ordinating complexes or combinations thereof; allylamines are selected from the group consisting of terbinafine, amorolfine, naftifine and combinations thereof; the benzylamine is butenafine; the azoles are imidazoles, triazoles or thiazoles selected from the group consisting of ketoconazole, climbazole, miconazole nitrate, fluconazole, econazole, saperconazole, oxiconazole, clotrimazole, bifonazole, butoconazole, fenticonazole, isoconazole, omoconazole, sertaconazole, sulconazole, tioconazole, Miconazole, chlormidazole, croconazole, eberconazole, omoconazole, isoconazole, neticonazole, albaconazole, efmaconazole, fosfluconazole, epoxiconazole, fluconazole, isavuconazole, itraconazole, posaconazole, propiconazole, ravuconazole, terconazole, voriconazole, hexaconazole, abafungin and combinations thereof; the polyenes are selected from the group consisting of amphotericin B, natamycin, nystatin and combinations thereof; and the echinocandins are selected from the group consisting of caspofungin, anidulafungin, micafungin and combinations thereof.
12. The antifungal composition of any of the preceding claims, wherein the antifungal agent is selected from the group consisting of piroctone olamine, zinc pyrithione, ketoconazole, clotrimazole, Miconazole, terbinafine, efmaconazole, bifonazole, amphotericin B, caspofungin, ciclopirox olamine, climbazole, miconazole nitrate,

itraconazole, fluconazole, econazole, terconazole, saperconazole, amorolfine, oxiconazole, butenafine, nafiifine and combinations thereof.
13. The antifungal composition of claim 1, wherein the excipient is selected from the group consisting of additive, solvent, oil, emulsifier, surfactant, stabilizer, cooling agent, preservative, antioxidant, gelling agent, moisturizing agent, emollient, penetration enhancer, colorant, fragrance, pH modifiers, conditioning agent, pearlizing agents, skin barrier repair agents, and combinations thereof.
14. The antifungal composition of any of the preceding claims, wherein the excipient is additive selected from the group consisting of paraffin, thickeners selected from bentonite and cellulose, antioxidants selected from butylated hydroxyanisole (BHA), tert-butylhydroquinone (TBHQ), ferulic acid, tocopherol acetate or any combination of antioxidants thereof, perfumes or fragrances, essential oils, pH adjusters selected from triethanolamine, sodium hydroxide, inorganic or organic acids including citric acid, lactic acid, succinic acid, acetic acid, fumaric acid, glycolic acid, benzoic acid, bases, salts buffers or any combination of pH adjusters thereof, herbal extracts selected from amla fruit extract, arnica extract and brahmi extract, preserving agents selected from butylated hydroxytoluene (BHT), methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid or any combination of preserving agents thereof, hair conditioning substances, hair care adjuncts selected from taurine, caffeine, minoxidil, azelaic acid, marine cartilage, hydrolysed keratin, biotin, niacin, panthenol, vitamin B6, zinc, copper, peptides, horsetail silica, beta sitosterols, pycnogenol, PABA, green tea extract, folic acid, iron, L-cysteine, magnesium, ginseng or any combination of hair care adjuncts thereof, skin care adjuncts selected from proteins, vitamins including A, B, C, D, E and K, trace metals including zinc, calcium and selenium, moisturizers, LTV absorbers including paraminobenzoic acid (PABA), titanium dioxide, zinc oxide, anti-irritants including steroids and non-steroidal anti-inflammators, botanical extracts including aloe vera, chamomile, cucumber extract, ginkgo biloba, ginseng and rosemary, absorbents including aluminum starch octenylsuccinate, kaolin, corn starch, oat starch, cyclodextrin, talc and zeolite, skin bleaching and lightening agents including hydroquinone and niacinamide lactate, humectants including sorbitol, urea and manitol, exfoliants, cooling agents selected from menthol, menthol derivatives, WS 3, WS -5, WS 14, WS 23, MHB, frescolat MGA, 2S MPD, coolcat P, WS 30, PM 38, skin conditioning agents selected from aloe extract, allantoin, bisabolol, shea butter,

ceramides, sphingosine, dimethicone, hyaluronic acid and dipotassium glycyrrhizate, natural components including oatmeal, or any combination of skin care adjuncts thereof, emollient, dyestuffs, moisturizers, vitamins, sphingoceryls, sunscreens, co-surfactants, foaming agents, co-emulsifiers, viscosity modifiers, suspending agents, potentiating agents, pearlizing agents, cooling agents, ionic strength modifiers and oil-soluble polymers which are compatible with the base oil or skin care agents or both including skin-nutrient agents, anti-wrinkle agents, light and dust protectors, and combinations thereof; solvent selected from the group consisting of ethanol, isopropyl alcohol, butanol, C-l to C-6 lower aliphatic alcohols, lower alkyl acetate, ethers, carboxylic acid, derivatives containing carbon chain length less than C15, fatty alcohols selected from the group consisting of undecanol, oleyl alcohol and lauryl alcohol, or any combination of solvents thereof; emulsifier selected from the group consisting of steareth-2, steareth-21, poloxamer, macrogolcetostearyl ether 20, cetyl alcohol cetearths, ceteth, isoceteths, laureths, oleths, steareths, lauramide DEA, linoleamide DEA or any combination of emulsifiers thereof; surfactant selected from the group consisting of poloxamer, PEG-2 stearyl ether, PEG-21 stearyl ether, pluoronic F127 (poloxamer), polyoxyl 20 cetosteryl ether, sodium laryl ether sulphate, coco monoethanolamide, cocamidopropylbetain, sodium docusate, ammonium lauryl sulphate, coco glucoside, lauryl glucoside, decyl glucoside, caprylyl capryl glucoside, sodium cocoyl glutamate, disodium cocoyl glutamate, sodium lauroamphoacetate, sodium cocoamphoacetate, disodium cocoamphoacetate, disodium laureth sulfosuccinate, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium cocoyl isethionate, ammonium cocoyl isethionate, sodium lauryl glucose carboxylate, sodium lauroyl lactylate, sodium lauroyl sarcosinate, sodium lauroyl methyl isethionate, sodium cocoyl glycinate, or any combination of surfactants thereof; surfactant and co-surfactant blend selected from Iselux SLC consisting of sodium lauroyl methyl isethionate, sodium lauroamphoacetate, cocamide MIPA and water, Miracare SLB 365/N consisting of sodium trideceth sulfate, sodium lauroamphoacetate, cocamide MEA, sodium chloride, methylisothiazolinone and water, or a combination of blend thereof; oil including natural or synthetic oils selected from the group consisting of eucalyptus oil, rosemary oil, pine needle oil, tea tree oil, sage oil, cinnamon oil, lemon oil, citronella oil, lime oil, orange oil, peppermint oil, spearmint oil, wintergreen oil, sweet birch oil, clove leaf oil, camphor oil, cardamon

oil, cedar leaf oil, sweet birch oil, paraffin oil, silicone oil or any combination of oils thereof; polymer selected from the group consisting of PEG, cellulose derivatives, acrylic based polymers, poloxamers, and combinations thereof; stabilizer selected from the group consisting of metal chelators, acrylic and cellulose derivatives, sodium carboxy methyl cellulose, poly vinyl alcohol, xanthan gum, guar gum, locust bean gum and combinations thereof; and active agent selected from the group consisting of pharmaceutical active, OTC active, anti-bacterial agent including benzothenium chloride, anti-inflammatory agent, skin penetration enhancer and combinations thereof.
15. The antifungal composition of any of the preceding claims, wherein the composition comprises about 0.01% to 20% by weight of the antifungal agent.
16. The antifungal composition of any of the preceding claims, wherein the composition comprises about 0.01% to 15% by weight of the antifungal agent.
17. The antifungal composition of any of the preceding claims, wherein the composition comprises about 0.01% to 30% by weight of the saturated or unsaturated fatty acid or ester thereof.
18. The antifungal composition of any of the preceding claims, wherein the composition comprises about 0.01% to 20% by weight of the saturated or unsaturated fatty acid or ester thereof.
19. The antifungal composition of any of the preceding claims, wherein the composition comprises about 45% to 99% by weight of the excipient.
20. The antifungal composition of any of the preceding claims, wherein the composition comprises about 80% to 99% by weight of the excipient.
21. The antifungal composition of any of the preceding claims, wherein the composition comprises caprylic acid or an ester thereof and antifungal agent selected from the group consisting of allylamines, benzylamines, azoles, polyenes, echinocandins, 7V-hydroxy pyridones, 7V-hydroxy pyrithiones and combinations thereof, and optionally at least one excipient.
22. The antifungal composition of any of the preceding claims, wherein the composition comprises caprylic acid or an ester thereof and antifungal agent selected from the group consisting of terbinafine, butenafine, clotrimazole, ketoconazole, luliconazole, bifonazole, efinaconazole, amphotericin B, caspofungin, zinc pyrithione, piroctone olamine and combinations thereof, and optionally at least one excipient.

23. The antifungal composition of any of the preceding claims, wherein the composition comprises propylene glycol monocaprylate and antifungal agent selected from the group consisting of allylamines, benzylamines, azoles, polyenes, echinocandins, N-hydroxy pyridones, 7V-hydroxy pyrithiones and combinations thereof, and optionally at least one excipient.
24. The antifungal composition of any of the preceding claims, wherein the composition comprises propylene glycol monocaprylate and antifungal agent selected from the group consisting of terbinafine, butenafine, clotrimazole, ketoconazole, Miconazole, bifonazole, efinaconazole, amphotericin B, caspofungin, zinc pyrithione, piroctone olamine and combinations thereof, and optionally at least one excipient.
25. The antifungal composition of any of the preceding claims, wherein the composition comprises lauric acid or propylene glycol monolaurate, and antifungal agent selected from the group consisting of allylamines, benzylamines, azoles, polyenes, echinocandins, 7V-hydroxy pyridones, 7V-hydroxy pyrithiones and combinations thereof, and optionally at least one excipient.
26. The antifungal composition of any of the preceding claims, wherein the composition comprises lauric acid or propylene glycol monolaurate and antifungal agent selected from the group consisting of terbinafine, butenafine, clotrimazole, ketoconazole, Miconazole, bifonazole, efinaconazole, amphotericin B, caspofungin, zinc pyrithione, piroctone olamine and combinations thereof, and optionally at least one excipient.
27. The antifungal composition of any of the preceding claims, wherein the composition comprises fatty acid ester selected from the group consisting of glyceryl monocaprylate, glyceryl monolaurate, glyceryl monocaprate, glyceryl dicaprylate, glyceryl dilaurate, glyceryl dicaprate, glyceryl mono and di caprate, glyceryl mono and di caprylate and glyceryl mono and di laurate, triglycerides of caprylic acid, capric acid, lauric acid and their mixtures, and antifungal agent selected from the group consisting of allylamines, benzylamines, azoles, polyenes, echinocandins, 7V-hydroxy pyridones, 7V-hydroxy pyrithiones and combinations thereof, and optionally at least one excipient.
28. The antifungal composition of any of the preceding claims, wherein the composition comprises fatty acid ester selected from the group consisting of glyceryl monocaprylate, glyceryl monolaurate, glyceryl dicaprylate, glyceryl dilaurate, glyceryl monocaprate, glyceryl dicaprate, glyceryl mono and di caprate, glyceryl mono and di caprylate and glyceryl mono and di laurate, triglycerides of caprylic acid, capric acid, lauric acid and

their mixtures, and antifungal agent selected from the group consisting of terbinafine, butenafine, clotrimazole, ketoconazole, luliconazole, bifonazole, efinaconazole, amphotericin B, caspofungin, zinc pyrithione, piroctone olamine and combinations thereof, and optionally at least one excipient.
29. The antifungal composition of any of the preceding claims, wherein the composition comprises capric acid or an ester thereof and antifungal agent selected from the group consisting of allylamines, benzylamines, azoles, polyenes, echinocandins, 7V-hydroxy pyridones, 7V-hydroxy pyrithiones and combinations thereof, and optionally at least one excipient.
30. The antifungal composition of any of the preceding claims, wherein the composition comprises capric acid or an ester thereof and antifungal agent selected from the group consisting of terbinafine, butenafine, clotrimazole, ketoconazole, luliconazole, bifonazole, efinaconazole, amphotericin B, caspofungin, zinc pyrithione, piroctone olamine and combinations thereof, and optionally at least one excipient.
31. The antifungal composition of any of the preceding claims, wherein the composition comprises undecylenic acid or an ester thereof and antifungal agent selected from the group consisting of allylamines, benzylamines, azoles, polyenes, echinocandins, N-hydroxy pyridones, 7V-hydroxy pyrithiones and combinations thereof, and optionally at least one excipient.
32. The antifungal composition of any of the preceding claims, wherein the composition comprises undecylenic acid or an ester thereof and antifungal agent selected from the group consisting of terbinafine, butenafine, clotrimazole, ketoconazole, luliconazole, bifonazole, efinaconazole, amphotericin B, caspofungin, zinc pyrithione, piroctone olamine and combinations thereof, and optionally at least one excipient.
33. The antifungal composition of any of the preceding claims, wherein the composition comprises (a) piroctone olamine, propylene glycol monocaprylate and at least one excipient, (b) zinc pyrithione, propylene glycol monocaprylate and at least one excipient, (c) ketoconazole, propylene glycol monocaprylate and at least one excipient, (d) ketoconazole, zinc pyrithione, propylene glycol monocaprylate and at least one excipient, (e) clotrimazole, propylene glycol monocaprylate and at least one excipient, (f) luliconazole, propylene glycol monocaprylate and at least one excipient, (g) terbinafine, propylene glycol monocaprylate and at least one excipient, (h) efinaconazole, propylene glycol monocaprylate and at least one excipient, (i)

itraconazole, propylene glycol monocaprylate and at least one excipient, (j) amphotericin B, propylene glycol monocaprylate and at least one excipient, (k) caspofungin, propylene glycol monocaprylate and at least one excipient, (1) ciclopirox olamine, propylene glycol monocaprylate and at least one excipient, (m) butenafine, propylene glycol monocaprylate and at least one excipient, (n) ketoconazole, propylene glycol monocaprylate, glyceryl mono and di caprate/caprylate and at least one excipient, or (o) ketoconazole, zinc pyrithione, propylene glycol monocaprylate, glyceryl mono and di caprate, glyceryl mono and di caprylate and at least one excipient.
34. The antifungal composition of any of the preceding claims, wherein the composition comprises (a) piroctone olamine, glyceryl monocaprylate or glyceryl mono and di caprate or glyceryl mono and di caprylate, and at least one excipient, (b) zinc pyrithione, glyceryl monocaprylate and at least one excipient, (c) ketoconazole, glyceryl monocaprylate and at least one excipient, (d) ketoconazole, zinc pyrithione, glyceryl monocaprylate and at least one excipient, (e) clotrimazole, glyceryl monocaprylate and at least one excipient, (f) Miconazole, glyceryl monocaprylate and at least one excipient, (g) terbinafine, glyceryl monocaprylate and at least one excipient, (h) efinaconazole, glyceryl monocaprylate and at least one excipient, (i) caspofungin, glyceryl monocaprylate and at least one excipient, (j) ciclopirox olamine, glyceryl monocaprylate and at least one excipient, (k) butenafine, glyceryl monocaprylate and at least one excipient, (1) terbinafine, glyceryl monocaprylate and at least one excipient, (m) butenafine, caprylic acid and at least one excipient, (n) terbinafine, caprylic acid and at least one excipient, (o) Miconazole, caprylic acid and at least one excipient, (p) clotrimazole, caprylic acid and at least one excipient, (q) efinaconazole, caprylic acid and at least one excipient, (r) ketoconazole, caprylic acid and at least one excipient, (s) ketoconazole, caprylic acid, propylene glycol monocaprylate and at least one excipient, (t) piroctone olamine, ketoconazole, caprylic acid and at least one excipient, (u) piroctone olamine, ketoconazole, caprylic acid, propylene glycol monocaprylate and at least one excipient, or (v) itraconazole, caprylic acid and at least one excipient.
35. The antifungal composition of any of the preceding claims, wherein the composition comprises (a) piroctone olamine, undecylenic acid and at least one excipient, (b) zinc pyrithione, undecylenic acid and at least one excipient, (c) ketoconazole, undecylenic acid and at least one excipient, (d) ketoconazole, zinc pyrithione, undecylenic acid and at least one excipient, (e) clotrimazole, undecylenic acid and at least one excipient, (f)

Miconazole, undecylenic acid and at least one excipient, (g) terbinafine, undecylenic acid and at least one excipient, (h) efinaconazole, undecylenic acid and at least one excipient, (i) itraconazole, undecylenic acid and at least one excipient, (j) amphotericin B, undecylenic acid and at least one excipient, (k) caspofungin, undecylenic acid and at least one excipient, or (1) ciclopirox olamine, undecylenic acid and at least one excipient.
36. The antifungal composition of any of the preceding claims, wherein the composition comprises (a) piroctone olamine, lauric acid or propylene glycol monolaurate and at least one excipient, (b) zinc pyrithione, lauric acid or propylene glycol monolaurate and at least one excipient, (c) ketoconazole, lauric acid or propylene glycol monolaurate and at least one excipient, (d) ketoconazole, zinc pyrithione, lauric acid or propylene glycol monolaurate and at least one excipient, (e) clotrimazole, lauric acid or propylene glycol monolaurate and at least one excipient, (f) Miconazole, lauric acid or propylene glycol monolaurate and at least one excipient, (g) terbinafine, lauric acid or propylene glycol monolaurate and at least one excipient, (h) efinaconazole, lauric acid or propylene glycol monolaurate and at least one excipient, (i) itraconazole, lauric acid or propylene glycol monolaurate and at least one excipient, (j) amphotericin B, lauric acid or propylene glycol monolaurate and at least one excipient, (k) caspofungin, lauric acid or propylene glycol monolaurate and at least one excipient, (1) ciclopirox olamine, lauric acid or propylene glycol monolaurate and at least one excipient, (m) clotrimazole, a fatty acid or ester selected from the group consisting of propylene glycol monolaurate, glycerol monolaurate, propylene glycol monocaprylate, glyceryl monocaprylate, glyceryl mono and di caprylate/caprate or any combination thereof, and at least one excipient, (n) Miconazole, a fatty acid or ester selected from the group consisting of propylene glycol monocaprylate, propylene glycol monolaurate, glyceryl monocaprylate, glyceryl mono and di caprylate/caprate or any combination thereof, and at least one excipient, or, (o) terbinafine, a fatty acid or ester selected from the group consisting of propylene glycol monocaprylate, glycerol caprylate/caprate or a combination thereof, and at least one excipient.
37. The antifungal composition of any of the preceding claims, wherein the composition comprises: (a) clotrimazole, (b) propylene glycol monocaprylate, and at least one excipient.

38. The antifungal composition of any of the preceding claims, wherein the composition comprises: (a) luliconazole, (b) propylene glycol monocaprylate, and at least one excipient.
39. The antifungal composition of any of the preceding claims, wherein the composition comprises: (a) terbinafine, (b) propylene glycol monocaprylate, and at least one excipient.
40. The antifungal composition of any of the preceding claims, wherein the composition comprises: (a) efinaconazole, (b) propylene glycol monocaprylate, and at least one excipient.
41. The antifungal composition of any of the preceding claims, wherein the composition comprises: (a) ketoconazole, (b) zinc pyrithione, (c) propylene glycol monocaprylate, and at least one excipient.
42. The antifungal composition of any of the preceding claims, wherein the composition comprises: (a) piroctone olamine, (b) propylene glycol monocaprylate, and at least one excipient, wherein said excipient comprises benzothenium chloride.
43. The antifungal composition of any of the preceding claims, wherein the composition comprises: (a) allylamine or benzylamine antifungal agent, (b) undecylenic acid, and at least one excipient; wherein the allylamine or benzylamine is terbinafine, butenafine or a combination thereof.
44. The antifungal composition of any of the preceding claims, wherein the composition comprises: (a) imidazole antifungal agent, (b) undecylenic acid, and at least one excipient; wherein the imidazole is ketoconazole, clotriconazole, luliconazole or any combination thereof.
45. The antifungal composition of any of the preceding claims, wherein the composition comprises: (a) triazole antifungal agent, (b) fatty acid or ester thereof selected from a group consisting of caprylic acid, lauric acid, propylene glycol monocaprylate, glyceryl monocaprylate, propylene glycol monolaurate, undecylenic acid and combinations thereof, and at least one excipient.
46. The antifungal composition of claim 45, wherein the triazole is efinaconazole, itraconazole, or a combination thereof.
47. The antifungal composition of any of the preceding claims, wherein the composition is devoid of C-15 or greater fatty acids, or C-15 or greater fatty acid esters.

48. The antifungal composition of any of the preceding claims, wherein the composition is formulated for topical administration, local administration, systemic administration, or any combination thereof.
49. The antifungal composition of any of the preceding claims, wherein the composition is formulated into cream, oil, lotion, serum, gel, emugel, hydrogel, shampoo, nail varnish, ointment, foam, spray, aerosol, coating for material selected from surgical implants, silicon tube, catheter, valves, stents, or suture; or any combination of formulations thereof.
50. A method for treating a fungal infection in a subject in need thereof or managing fungal growth, comprising administering the antifungal composition of any of the preceding claims to the subject, or contacting the antifungal composition of any of the preceding claims with the fungus.
51. The method of any of the preceding claims, wherein the treating or managing comprises inhibiting the fungal growth, reducing the fungal growth, eliminating the fungus, curing drug resistant fungal infections, treatment of fungal infections in clinical non-responders and patients with barrier defects, or any combination thereof.
52. The method of any of the preceding claims, wherein the treatment includes medical treatment, cosmetic treatment, or a combination thereof.
53. The method of any of the preceding claims, wherein the fractional inhibitory concentration (FIC) index of the composition is less than 1.
54. The method of any of the preceding claims, wherein the fungal infection or fungal growth is caused by fungi selected from the group consisting of Malassezia species, Trichophyton species, Microsporum species, Epidermophyton species, Candida species, Aspergillus species, Cryptococcus species and combinations thereof.
55. The method of any of the preceding claims, wherein the fungal infection or fungal growth is caused by Malassezia spp. selected from the group consisting ofM furfur, M. pachydermatis, M. globosa, M. restricta, M. slooffiae, M. sympodialis, M. nana, M. yamatoensis, M. dermatis, M. obtusa, M. japonica, M. caprae, M. cuniculi, M. equine, andM arunalokei; Trichophyton spp. selected from the group consisting of T. rubrum, T mentagrophyte, T interdigitale, T. tonsurans, T schoenleinii, T. violaceum, T. abissinicum, T. balcaneum, T. circonvolutum, T. concentricum, T. eboreum, T. errinacei, T.fischeri, T. fluviomuniense, T. glabrum, T. gourvilii, T kanei, T. kuryangei, T. megninii, T. pedis, T. proliferans, T. raubitschekii, T. redellii, T. rodhainii, T. simii,

T. soudanense, T. thuringiense, T. verrucosum, T. violaceum and Trichophyton yaoundei; Candida spp. selected from the group consisting of C. albicans, C. glabrata, C. guilliermondii, C. krusei, C. lusitaniae, C. parapsilosis, C. tropicalis, C. colliculosa, C. dubliniensis, C. famata, C. haemulonii, C. inconspicua, C. intermedia, C. kefyr, C. lipolytica, C. metapsilosis, C. norvegensis, C. orthopsilosis, C. pelliculosa, C. pulcherrima, C. rugose, C. utilis, C. viswanathii, andC. zeylanoides;Microsporum spp. selected from the group consisting of M. audouinii, M. canis, M. amazonicum, M. boullardii, M. cookie, M. distortum, M. duboisii, M. equinum, M. ferrugineum, M. fulvum, M. gallinae, M. gypseum, M. langeronii, M. nanum, M. persicolor, M. praecox, M. ripariae andM rivalieri; Epidermaphyton spp such as E. floccosum; and other non-dermatophytes including but not limited to Aspergillus spp. selected from the group consisting of A. fumigates, A. flavus, A. nidulans,A. terreus, A. lentulus, A. niger, A. alliaceus, A. arvii, A. brevipes, A. calidoustus, A. conjunctus, A. deflectus, A. duricaulis, A. emericella, A. fischerian, A. fumigatiaffmis, A. fumisynnematus, A. granulosus, A. novofumigatus, A. panamensis, A. quadrilineatus, A. udagawae, A. unilateralis and A. ustus; and Cryptococcus spp. selected from the group consisting of C. neoformans, C. gattii, C. albidus, C. bacillisporus, C. decagatti, C. deuterogatti, C. laurentii, C. tetragatti and C. uniguttulatus; or any combination of fungi thereof.
56. The method of any of the preceding claims, wherein the fungus is resistant or susceptible to the antifungal agent comprised in the antifungal composition.
57. The method of any of the preceding claims, wherein the subject is mammal including human.
58. An antifungal composition according to any of the preceding claims for use as a medicament.
59. An antifungal composition according to any of the preceding claims for use in treating fungal infection.
60. Use of an antifungal composition of any of the preceding claims for managing fungus growth.
61. The use according to any of the preceding claims, wherein the fungal infection is caused by fungi selected from the group consisting of Malassezia species, Trichophyton species, Microsporum species, Epidermophyton species, Candida species, Aspergillus species, Cryptococcus species and combinations thereof.

62. A method of preparing the antifungal composition of any of the preceding claims,
comprising either of:
a) mixing at least one antifungal agent, at least one fatty acid or ester thereof, and optionally one or more excipient, in any order; wherein the fatty acid has a carbon chain length ranging from C-l to C-14; or
b) adding at least one fatty acid or ester thereof to a composition comprising at least one antifungal agent, wherein the fatty acid has a carbon chain length ranging from C-l to C-14; or
c) replacing C-l5 or greater fatty acid or ester thereof with at least one C-l to C-14 fatty acid or ester thereof, in a composition comprising at least one antifungal agent and said C15 or greater fatty acid or ester thereof,
to obtain the antifungal composition.
63. The method of claim 62, wherein the at least one fatty acid or ester thereof being mixed or added or replaced has a carbon chain length ranging from C-l 1 to C-14, or C-8 to C-10.
64. The method of claim 62, wherein concentration of the at least one antifungal agent is about 0.01% to 20%, concentration of the at least one fatty acid or ester thereof is about 0.01% to 30%, and concentration of the one or more excipient is about 45% to 99%, wherein the fatty acid has a carbon chain length ranging from C-l to C-14.